On January 28, 2025, Humacyte, Inc. announced an expanded partnership with Pluristyx, Inc. This collaboration focuses on supporting the development of Humacyte's investigational BioVascular Pancreas (BVP) for the potential treatment of insulin-dependent diabetes.
Pluristyx is performing gene editing of its PluriBank iPSC lines to block Human Leukocyte Antigen (HLA) markers expression, aiming to create immune-evading iPSCs. Humacyte is optimizing a process to differentiate these iPSCs into a pancreatic islet component for the BVP, designed to normalize glucose levels.
The BVP program aims to enable the delivery and survival of insulin-producing islets using Humacyte's acellular tissue engineered vessel (ATEV) as a carrier. This partnership highlights Humacyte's strategy to grow its pipeline with advanced tissue and organ systems, leveraging cutting-edge stem cell and gene editing technologies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.